AU5442501A - Eliciting HCV-specific antibodies - Google Patents

Eliciting HCV-specific antibodies

Info

Publication number
AU5442501A
AU5442501A AU54425/01A AU5442501A AU5442501A AU 5442501 A AU5442501 A AU 5442501A AU 54425/01 A AU54425/01 A AU 54425/01A AU 5442501 A AU5442501 A AU 5442501A AU 5442501 A AU5442501 A AU 5442501A
Authority
AU
Australia
Prior art keywords
hcv
antibodies
specific antibodies
eliciting
nob
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54425/01A
Other languages
English (en)
Inventor
Sergio Abrignani
Jens Heile
Michael Houghton
Derek O'hagan
Mark Selby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU5442501A publication Critical patent/AU5442501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU54425/01A 1999-12-01 2000-12-01 Eliciting HCV-specific antibodies Abandoned AU5442501A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16823499P 1999-12-01 1999-12-01
US60/168234 1999-12-01
US18505500P 2000-02-25 2000-02-25
US60/185055 2000-02-25
PCT/US2000/042541 WO2001047551A2 (en) 1999-12-01 2000-12-01 Eliciting antibodies specific for hepatitis c virus (hcv)

Publications (1)

Publication Number Publication Date
AU5442501A true AU5442501A (en) 2001-07-09

Family

ID=26863907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54425/01A Abandoned AU5442501A (en) 1999-12-01 2000-12-01 Eliciting HCV-specific antibodies

Country Status (12)

Country Link
US (3) US7329408B2 (https=)
EP (1) EP1233782B1 (https=)
JP (1) JP2004500366A (https=)
AT (1) ATE413190T1 (https=)
AU (1) AU5442501A (https=)
CA (1) CA2393251C (https=)
CY (1) CY1108734T1 (https=)
DE (1) DE60040755D1 (https=)
DK (1) DK1233782T3 (https=)
ES (1) ES2319727T3 (https=)
PT (1) PT1233782E (https=)
WO (1) WO2001047551A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
SK15762003A3 (sk) * 2001-06-29 2005-01-03 Chiron Corporation Kompozícia vakcíny HCV E1E2
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
US7598362B2 (en) 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
EP2263687B1 (en) * 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
WO2004065578A2 (en) * 2003-01-14 2004-08-05 Chiron Corporation Microparticles comprising polynucleotide adsorbed on the surface of or entrapped within the microparticles
WO2004071414A2 (en) * 2003-02-05 2004-08-26 Genzyme Corporation Therapeutic anti-hcv (al9) compounds
WO2004091491A2 (en) * 2003-04-10 2004-10-28 Transform Pharmaceuticals, Inc. Profiling conformational variants, antibody compositions and methods of using the same
CA2523266A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
JP5557415B2 (ja) * 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
CA2566725A1 (en) * 2004-05-17 2005-12-01 Chiron Corporation Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
US20080154210A1 (en) 2004-05-28 2008-06-26 Oryxe Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
DE602005026545D1 (de) * 2004-08-24 2011-04-07 Tokyo Metropolitan Org Med Res Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
CA2587712C (en) * 2004-11-18 2013-02-12 National University Of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
US8178086B2 (en) * 2006-01-04 2012-05-15 Novartis Vaccines And Diagnostics, Inc. Activation of HCV specific T cells
US20100291545A1 (en) 2007-07-25 2010-11-18 Takaji Wakita Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
EP2495256A4 (en) 2009-10-30 2013-09-25 Toray Industries ANTIBODIES WITH HEMMETAL EFFECT ON INFECTIONS WITH HEPATITIS C VIRUS (HCV) AND ITS USE
CN104324373B (zh) * 2010-11-26 2018-10-09 麦克法兰博尼特医学健康研究公司 组合物及其制备方法
CN105658230B (zh) 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
US5471330A (en) 1993-07-29 1995-11-28 Honeywell Inc. Polysilicon pixel electrode
DE69534296T2 (de) * 1994-07-29 2006-04-27 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Sezernierter E1/E2-Komplex des Hepatitis C-Virus, des aus C-terminal verkürzten Polypeptiden E1 und E2 erhalten ist
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
DE69608122T3 (de) * 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
DE69841015D1 (de) * 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
WO1999004010A1 (en) * 1997-07-18 1999-01-28 Connaught Laboratories Limited Nucleic acid vaccines encoding g protein of respiratory syncytial virus
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies

Also Published As

Publication number Publication date
CY1108734T1 (el) 2014-04-09
US20080095800A1 (en) 2008-04-24
EP1233782A2 (en) 2002-08-28
ES2319727T3 (es) 2009-05-12
PT1233782E (pt) 2009-02-13
CA2393251A1 (en) 2001-07-05
DE60040755D1 (de) 2008-12-18
US20110159039A1 (en) 2011-06-30
CA2393251C (en) 2012-01-31
WO2001047551A2 (en) 2001-07-05
WO2001047551A3 (en) 2002-03-14
JP2004500366A (ja) 2004-01-08
US20020002272A1 (en) 2002-01-03
DK1233782T3 (da) 2009-02-09
ATE413190T1 (de) 2008-11-15
US7329408B2 (en) 2008-02-12
EP1233782B1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
CY1108734T1 (el) Αναπτυξη αντισωματων ειδικων για hcv
WO2001098333A3 (en) Modification of hepatitis b core antigen
WO2002061576A3 (en) System, method and article of manufacture for interface constructs in a programming language capable of programming hardware architectures
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
DE3268361D1 (en) New vaccine and therapy against non-a non-b viral hepatitis, and their preparation process
WO1993001210A3 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
IL152825A0 (en) Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
WO2002000242A3 (en) Human papilloma virus treatment
DE69531235D1 (de) Säugetier - Expressionssysteme für Hüllenprotingene des Hepatitit - C - Virus
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
AUPQ797700A0 (en) Vaccine
EP0402029A3 (en) Monoclonal antibodies for post exposure treatment of rabies
WO1996019498A3 (en) T cell stimulating protein of pestivirus
DE60324003D1 (en) Hcv-test
EP0315242A3 (en) Process for purifying recombinant hepatitis antigens
EP0335135A3 (en) Production of monoclonal antibodies specific for non-a, non-b hepatitis infected liver
WO2003040341A3 (en) Anti-hepatitis a virus antibodies
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
WO2002100900A3 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
EP0339668A3 (en) Hepatitis a virus antigen
WO2004037202A3 (en) Gb virus c and methods of treating viral infections
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
WO2003014728A1 (fr) Medicaments contre l'hepatite c
WO2002051865A3 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
DE68918440D1 (de) Verfahren zur transformation von menschlichen b-lymphocyten.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase